Delivery Order SPE2DR25D2206-SPE2DR26F9FS4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order has a ceiling value of $87,963.69 and an ultimate completion date of December 10, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $13,012.76 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for supply of RINVOQ ER 15 mg tablets in quantities of 30-unit bottles. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of December 2, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $6,558.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 8, 2025, with completion targeted for December 9, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a $21,799.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of RINVOQ ER 30 mg tablets in units of 30. This competitively awarded, non-set-aside contract is scheduled for completion by December 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $28,761.77 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for RINVOQ ER 15 mg tablets (30-unit packaging), with a completion date of December 3, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's substantial pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed price contract valued at $11,902.23. This is a non-set-aside competitive award with an ultimate completion date of December 11, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units. The contract is valued at $155,311.70 and utilizes firm fixed price terms, with an ultimate completion date of December 2, 2025. This is an unset-aside, competitively awarded delivery order, indicating that AmerisourceBergen competed against other qualified vendors to secure this pharmaceutical supply requirement. The place...
- The Defense Logistics Agency awarded a $13,070.59 delivery order to AmerisourceBergen Drug Corp on June 13, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitive award utilizes firm fixed pricing with a completion date of June 16, 2025, and carries no set-aside designation. The delivery order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $23,153.27 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on December 8, 2025, with completion scheduled for December 9, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor will perform this...
- The Defense Logistics Agency awarded a $7,509.61 delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of RINVOQ ER 45 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with an ultimate completion date of December 10, 2025, and performance location in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation, reflecting AmerisourceBergen's capability to compete in open federal procurement. This delivery order...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9FS4Delivery Order
The Defense Logistics Agency awarded a $17,411.01 delivery order to AmerisourceBergen Drug Corp on December 12, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This firm fixed price contract, with an ultimate completion date of December 15, 2025, represents a non-set-aside competitive award for pharmaceutical products to support federal medical procurement needs. The delivery order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, AmerisourceBergen Drug Corp leverages this comprehensive global pharmaceutical support vehicle to supply a broad range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's consistent performance on competitive federal contracts and extensive pharmaceutical portfolio position it as a primary vendor supporting the Defense Health Agency and other federal healthcare systems through flexible, competitively awarded contract mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.4k | 12/11/25 |